Global Pharmaceutical Research Organization · Pharmaceutical Research
The organization was running a Phase III oncology trial with 48,200 patient records and 847 tracked biomarkers. Their analysis pipeline processed approximately 23% of records in their primary statistical models — a standard practice driven by the computational cost of full-cohort LLM-assisted analysis. The remaining 77% were included only in lower-resolution batch analyses that ran quarterly. A clinically significant biomarker interaction was present in the full dataset — but the combination of factors required to make it statistically significant only emerged at full coverage.
LLM reasoning applied to 100% of trial records across all 847 biomarkers simultaneously. The model was configured to identify multi-variable correlations that conventional statistical analysis — dependent on pre-specified hypotheses — would not surface.
"The interaction requires three biomarkers together. Any two of them alone — or in a sampled cohort — and the signal disappears. We needed 100% of the data to see it. Four years of analysis had missed it."
Chief Scientific Officer, Oncology Division
The identified interaction — a three-way relationship between BRCA2 mutation status, IL-6 pathway activity, and a specific HLA variant — predicted treatment response with 34% greater accuracy than the existing biomarker panel. The finding enabled a targeted patient selection strategy for subsequent trials, with projected impact on both trial success rates and the eventual treatment's clinical utility.